PreScience Labs Announced that the FDA Accepts IND Application for Novel Oncology Drug
7/24/2013 9:44:57 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
POTOMAC, Md.--(BUSINESS WIRE)--PreScience Labs, LLC (“PreScience”) announced today that the U.S. Food and Drug Administration (“FDA”) has approved its Investigational New Drug (“IND”) application for Phase I clinical evaluation of its anti-cancer drug 3-bromopyruvate (“3-BrPA” or “PSL-001”). This Phase I clinical trial will be conducted in patients with primary and/or metastatic liver cancer.
Help employers find you! Check out all the jobs and post your resume.
comments powered by